Prostatype announces the outcome of the exercise of warrants of series TO 1
On 17 February 2022, the exercise period for Prostatype Genomics AB’s (“the Company”) warrant of series TO 1 ended, which was issued in connection with the Company’s issue of units in September 2020. A total of 14,841 warrants of series TO 1 were exercised. Through the warrants of series TO 1, the Company will receive approximately SEK 162 thousand before issue costs.
CEO Fredrik Persson comments
“We work purposefully to create growth for the Company and we experience a clear demand for the Prostatype® Test System. In addition to the Nordic market, we now have a market presence in Germany, Italy, the United Kingdom, Spain and Portugal. With the issue proceeds from the directed issue that took place last year, we can continue to intensify the Prostatype® Test System in selected European markets as well as in the US and Asia. In terms of future development, we have great confidence, and our operational goals are running according to plan. The Board and I are continuously evaluating alternatives for raising capital.”
Option redemption of TO 1
In total, 14,841 warrants of series TO 1 were exercised during the exercise period. Through the exercise of warrants of series TO 1, the Company will thus receive SEK 162 thousand. When the new shares are registered with Bolagsverket, the Swedish Companies Registration Office, the total number of shares will amount to 15,103,602 and the share capital will amount to SEK 906,216.12. The planned conversion date from interim to common shares is expected to take place on 7 March 2022. The common shares are expected to be visible in each subscriber’s account around 9 March 2022.
Advisors and issues
Sedermera Corporate Finance has acted as financial advisor and Markets & Corporate Law Nordic Ab has acted as legal advisor to Prostatype Genomics in connection with the exercise of warrants of series TO 1. Nordic Issuing has acted issuing institution.
For more information regarding the warrants of series TO 1, please contact
Sedermera Corporate Finance
+46 (0) 40 615 14 10
cf@sedermera.se
www.sedermera.se
Nordic Issuing
+46 (0)40-632 00 20
info@nordic-issuing.se
www.nordic-issuing.se
Nicklas Rosendal
Press contact
nicklas.rosendal@prostatypegenomics.com
Certified Advisor
Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.